How much funding has Pyxis Oncology raised?

Pyxis Oncology has raised $174.0M in total funding, most recently a Series B round.

Who are Pyxis Oncology's investors?

Pyxis Oncology's investors include Leaps by Bayer, Arix Bioscience, RTW Investments, Longwood Fund, Agent Capital, Pfizer Ventures.

What industry is Pyxis Oncology in?

Pyxis Oncology operates in Biotech, Healthcare.

Pyxis Oncology

IPO

Charting a course to therapeutics for difficult-to-treat cancers

Biotech

Healthcare

Business Model: B2B
Website: pyxisoncology.com
Total Funding: $174.0M

Last Round: $152.0M Series BMar 2021
Rounds: 2

About

Pyxis Oncology is a clinical-stage biopharmaceutical company devoted to developing next-generation therapeutics for patients with difficult-to-treat cancers. The company has assembled a differentiated portfolio of clinical assets, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies designed to directly kill tumor cells and activate the immune system to overcome cancer's defense mechanisms. Its lead candidate MICVO and pipeline of immuno-oncology therapies are advanced as both monotherapies and combination treatments, targeting patients who lack effective options from existing therapies.

Summary

Pyxis Oncology is a Biotech company. It has raised $174.0M in total across 2 rounds, most recently a $152.0M Series B round in Mar 2021. Investors include Leaps by Bayer, Arix Bioscience and RTW Investments.

LinkedIn X (Twitter)